Loong, H. H., Wong, C. K. H., Leung, L. K. S., Tan, S. C., Jen, J., Lee, M. Y. K., . . . Wang, J. (2020). Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Eff Resour Alloc.

Loong, Herbert H., Carlos K. H. Wong, Linda K. S. Leung, S. C. Tan, Jason Jen, Mary Y. K. Lee, Raquel Aguiar-Ibáñez, ja Jingshu Wang. "Cost-effectiveness Analysis of Pembrolizumab Compared to Standard of Care As First Line Treatment for Patients With Advanced Melanoma in Hong Kong." Cost Eff Resour Alloc 2020.

Loong, Herbert H., et al. "Cost-effectiveness Analysis of Pembrolizumab Compared to Standard of Care As First Line Treatment for Patients With Advanced Melanoma in Hong Kong." Cost Eff Resour Alloc 2020.